Agilent Technologies Inc, a global analytical instrumentation manufacturing company, announced recently it will double the current capacity at its Fredrick, Colorado facility. This move will cultivate the growth of the “oligos” manufacturing which are used in developing treatments for cancer, COVID-19, and other conditions. Oligos are “short DNA & RNA molecules used to create nucleic acid-based therapeutics.” The demand for therapeutic oligos is projected to exceed $750 million by 2025.
Source: https://www.agilent.com/about/newsroom/presrel/2020/18aug-gp20017.html